Comparison of therapeutic effects of N-Acetylcysteine with pregabalin in improving the clinical symptoms of painful diabetic neuropathy: a randomized, double-blind clinical trial
Authors:
Open Access
- 19 April 2024
- journal article
- research article
- Published by Springer Nature in Clinical Diabetes and Endocrinology
- Vol. 10 (1) , 1-7
Abstract
Objectives: Painful diabetic neuropathy (PDN) is highly prevalent and annoyingly in patients with diabetes. The aim of this study was to investigate the effects of oral N-acetylcysteine (NAC) compared to pregabalin in PDN. Methods: One hundred two eligible patients with type 2 diabetes and PDN were randomly recievied pregabalin (150 mg/day) or N-Acetylcysteine (NAC) (600 mg/ twice a day) for 8 weeks. Mean pain score, Sleep interference score (SIS), Patient Global Impression of Change (PGIC), Clinical Global Impression of Change (CGIC), and also, serum levels of total antioxidant capacity (TAC), total thiol groups (TTG), catalase activity (CAT), nitric oxide (NO), and malondialdehyde (MDA) were assessed at baseline and at the end of the study. Results: NAC was well tolerated in all patients. The decrease in mean pain scores and increase in SIS was similar between two groups. More improvement in PGIC and CGIC from the baseline was reported in NAC group. NAC, significantly, decreased serum levels of MDA, and NO, but increased TAC, TTG, and CAT. Pregabalin, significantly, decreased serum levels of MDA, and NO and increased TAC. Discussion: NAC is efficacious in alleviate symptoms of PDN which is probably related to its antioxidant effects. Trial registration: The research protocol received approval from the Ethics Committee of Hamadan University of Medical Sciences (IR.UMSHA.REC.1397.137). The trial registry URL and number in Iranian Registry of Clinical Trials (IRCT): https://www.irct.ir/trial/33313, IRCT20180814040795N2 (Registration date: 2019-01-21, Retrospectively registered)Keywords
Funding Information
- Hamadan University of Medical Sciences (IR.UMSHA.REC.1397.137)
This publication has 33 references indexed in Scilit:
- A new look at painful diabetic neuropathyDiabetes Research and Clinical Practice, 2018
- N-Acetyl Cysteine Functions as a Fast-Acting Antioxidant by Triggering Intracellular H2S and Sulfane Sulfur ProductionCell Chemical Biology, 2018
- Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2016
- Effect of N-acetylcysteine on the spinal-cord glutathione system and nitric-oxide metabolites in rats with neuropathic painNeuroscience Letters, 2014
- Diabetic NeuropathyEndocrinology and Metabolism Clinics of North America, 2013
- The role of diet in the prevention of type 2 diabetesNutrition, Metabolism and Cardiovascular Diseases, 2011
- Neuroprotective effect of N-acetylcysteine in the development of diabetic encephalopathy in streptozotocin-induced diabetesMetabolic Brain Disease, 2008
- Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N‐acetyl‐l‐cysteine in ratsEuropean journal of pain, 2006
- Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trialPain, 2004
- Prediction of creatinine clearance from serum creatinine concentration based on lean body massClinical Pharmacology & Therapeutics, 1981